Peel Hunt reiterated their hold rating on shares of Vectura Group (LON:VEC) in a research report sent to investors on Thursday morning. They currently have a GBX 160 ($2.14) target price on the stock.
Several other analysts have also issued reports on VEC. Numis Securities restated a buy rating and issued a GBX 205 ($2.74) target price on shares of Vectura Group in a research note on Thursday, September 7th. Citigroup lowered their target price on Vectura Group from GBX 200 ($2.67) to GBX 180 ($2.41) and set a buy rating on the stock in a research note on Monday, September 18th. JPMorgan Chase & Co. lowered their target price on Vectura Group from GBX 210 ($2.81) to GBX 180 ($2.41) and set an overweight rating on the stock in a research note on Thursday, September 21st. Shore Capital restated a buy rating on shares of Vectura Group in a research note on Thursday, November 9th. Finally, Panmure Gordon reiterated a buy rating and set a GBX 150 ($2.01) price objective on shares of Vectura Group in a research note on Thursday, November 9th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of GBX 174 ($2.33).
Shares of Vectura Group (VEC) opened at GBX 116.64 ($1.56) on Thursday. Vectura Group has a one year low of GBX 86.50 ($1.16) and a one year high of GBX 166.97 ($2.23).
ILLEGAL ACTIVITY WARNING: “Vectura Group (VEC) Stock Rating Reaffirmed by Peel Hunt” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/08/vectura-group-vec-stock-rating-reaffirmed-by-peel-hunt.html.
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
What are top analysts saying about Vectura Group? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vectura Group and related companies.